<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1502028/" ref="ordinalpos=436&amp;ncbi_uid=703400&amp;link_uid=PMC1502028" image-link="/pmc/articles/PMC1502028/figure/F4/" class="imagepopup">Figure 4.  From: Disruption of Parallel and Converging <span class="highlight" style="background-color:">Signaling</span> Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells. </a></div><br /><div class="p4l_captionBody">Schematic of EGFR and mTOR signaling network, and signaling mediator effects associated with rapamycin and/or EKI-785 treatments. A notation of an “E” or “R,” in association with a signaling pathway, indicates where the pathway is blocked by EKI-785 or rapamycin, respectively.</div></div>